What is Erste Group Bank’s Estimate for ABT FY2027 Earnings?

Abbott Laboratories (NYSE:ABT) – Erste Group Bank upped their FY2027 earnings estimates for shares of Abbott Laboratories in a research note issued on Monday, July 27th. Erste Group Bank analyst H. Engel now anticipates that the healthcare product maker will earn $6.06 per share for the year, up from their prior forecast of $6.05. The consensus estimate for Abbott Laboratories’ current full-year earnings is $5.52 per share.

Several other brokerages have also commented on ABT. JPMorgan Chase & Co. upped their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Argus dropped their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Piper Sandler reissued an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Stock Up 2.7%

Shares of NYSE ABT opened at $107.34 on Wednesday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $186.97 billion, a PE ratio of 34.74, a P/E/G ratio of 2.02 and a beta of 0.61. The firm has a fifty day moving average of $92.32 and a 200-day moving average of $100.85. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period last year, the company earned $1.26 earnings per share. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS.

Institutional Investors Weigh In On Abbott Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares during the last quarter. State Street Corp increased its position in shares of Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after acquiring an additional 1,627,791 shares during the last quarter. Capital International Investors lifted its stake in shares of Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP boosted its holdings in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors grew its stake in Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Quarterly beat and higher outlook: Abbott reported second-quarter adjusted EPS of $1.31, ahead of the $1.28 consensus, while revenue rose 13% year over year to $12.59 billion. Management raised its full-year 2026 EPS outlook to $5.45-$5.60, supported by demand for cancer diagnostics and medical devices. Abbott Raised Its Profit Forecast
• Positive Sentiment: New colorectal cancer screening opportunity: Abbott secured exclusive U.S. commercialization rights for Freenome’s FDA-approved SimpleScreen blood-based colorectal cancer test. The product could expand Abbott’s diagnostics portfolio and address a large population overdue for screening. FDA Approves Freenome’s SimpleScreen
• Positive Sentiment: Analyst support and growth drivers: TD Cowen maintained a Buy rating with a $115 price target, citing strengthening nutrition operations and 2026 growth opportunities. Abbott’s diabetes care, oncology diagnostics and cardiovascular-device launches and acquisitions provide additional expansion avenues. TD Cowen Buy Rating
• Neutral Sentiment: Erste Group modestly raised its FY2027 EPS estimate to $6.06 from $6.05, signaling confidence but only a marginal change. The estimate remains above the current-year consensus of $5.52.
• Negative Sentiment: Valuation and target-price caution: UBS lowered its price target to $125 from $135 while retaining a Buy rating. With ABT trading at roughly 35 times earnings, investors may view the shares as offering more limited valuation upside after the earnings rally. UBS Price Target Update
• Negative Sentiment: Some coverage noted that litigation concerns and questions about procedure volumes could overshadow Abbott’s otherwise strong growth, creating near-term volatility.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.